Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study.

Joseph J

Cureus28 Jul 2025

PMID40777719PMCIDPMC12329614DOI10.7759/cureus.88893PepBankPUB-40777719

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) confer multiple cardiometabolic benefits beyond glycemic control, including weight reduction and potential cardiovascular protection. This case presents an 18-month follow-up of a 48-year-old obese male with type 2 diabetes mellitus (T2DM) and hypertension, who achieved sustained blood pressure (BP) control and lipid stability on semaglutide following discontinuation of triple antihypertensive therapy. At baseline, the patient had a BMI of 38 kg/m², BP of 156/96 mmHg, and an elevated glycosylated hemoglobin (HbA1c). Semaglutide was initiated at 0.25 mg weekly and titrated to 1 mg over six months. The patient exhibited progressive improvements in glycemic control, body weight, and BP, with HbA1c reduction and weight loss sustained over 18 months. Notably, BP remained consistently ≤130/80 mmHg, and lipid parameters remained stable without additional pharmacotherapy. This case underscores the potential of GLP-1 RAs to exert antihypertensive effects, possibly through weight loss, vascular endothelial function enhancement, and modulation of the renin-angiotensin-aldosterone system (RAAS). These findings support the evolving role of GLP-1 RAs as a multifaceted therapeutic option in managing T2DM with coexisting cardiovascular risk factors.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesEfficacy outcome
In a 48-year-old man with obesity, type 2 diabetes and hypertension, blood pressure stayed at or below 130/80 mmHg on semaglutide after triple antihypertensive therapy was stopped.
In plain wordsIn one man with obesity and type 2 diabetes, blood pressure stayed controlled on semaglutide after his three blood pressure medicines were stopped.
Peptide
Semaglutide
Outcome
DecreaseBlood pressure control over 18 months
Study
n = 1
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.25 mg weekly titrated to 1 mg over six months · 18 monthsAs given in this study (human).
Source sentences
Summary
Notably, BP remained consistently ≤130/80 mmHg, and lipid parameters remained stable without additional pharmacotherapy.
2 context sentences(design, population, supporting numbers)
Summary · context
This case presents an 18-month follow-up of a 48-year-old obese male with type 2 diabetes mellitus (T2DM) and hypertension, who achieved sustained blood pressure (BP) control and lipid stability on semaglutide following discontinuation of triple antihypertensive therapy.
Summary · context
Semaglutide was initiated at 0.25 mg weekly and titrated to 1 mg over six months.
Show in the study text Report a problemFND-4077771901
02HumanCase report or seriesEfficacy outcome
In the same patient, weight loss on semaglutide was sustained over 18 months.
In plain wordsIn this man, weight loss on semaglutide lasted for 18 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight over 18 months
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
0.25 mg weekly titrated to 1 mg over six months · 18 monthsAs given in this study (human).
Source sentences
Summary
The patient exhibited progressive improvements in glycemic control, body weight, and BP
3 context sentences(design, population, supporting numbers)
Summary · context
weight loss sustained over 18 months.
Summary · context
This case presents an 18-month follow-up of a 48-year-old obese male with type 2 diabetes mellitus (T2DM) and hypertension, who achieved sustained blood pressure (BP) control and lipid stability on semaglutide following discontinuation of triple antihypertensive therapy.
Summary · context
Semaglutide was initiated at 0.25 mg weekly and titrated to 1 mg over six months.
Show in the study text Report a problemFND-4077771902
03HumanCase report or seriesEfficacy outcome
In the same patient, HbA1c fell on semaglutide and the reduction was sustained over 18 months.
In plain wordsIn this man, HbA1c fell on semaglutide and stayed lower for 18 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c over 18 months
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.25 mg weekly titrated to 1 mg over six months · 18 monthsAs given in this study (human).
Source sentences
Summary
HbA1c reduction and weight loss sustained over 18 months.
3 context sentences(design, population, supporting numbers)
Summary · context
At baseline, the patient had a BMI of 38 kg/m², BP of 156/96 mmHg, and an elevated glycosylated hemoglobin (HbA1c).
Summary · context
This case presents an 18-month follow-up of a 48-year-old obese male with type 2 diabetes mellitus (T2DM) and hypertension, who achieved sustained blood pressure (BP) control and lipid stability on semaglutide following discontinuation of triple antihypertensive therapy.
Summary · context
Semaglutide was initiated at 0.25 mg weekly and titrated to 1 mg over six months.
Show in the study text Report a problemFND-4077771903
04HumanCase report or seriesEfficacy outcome
In the same patient, lipid parameters stayed stable on semaglutide without added drug therapy.
In plain wordsIn this man, blood fat levels stayed stable on semaglutide without extra medicines.
Peptide
Semaglutide
Outcome
No significant changeLipid parameters over 18 months
Study
n = 1
Outcome group
Lipids · Metabolic and weight
Studied dose
0.25 mg weekly titrated to 1 mg over six months · 18 monthsAs given in this study (human).
Source sentences
Summary
lipid parameters remained stable without additional pharmacotherapy.
2 context sentences(design, population, supporting numbers)
Summary · context
This case presents an 18-month follow-up of a 48-year-old obese male with type 2 diabetes mellitus (T2DM) and hypertension, who achieved sustained blood pressure (BP) control and lipid stability on semaglutide following discontinuation of triple antihypertensive therapy.
Summary · context
Semaglutide was initiated at 0.25 mg weekly and titrated to 1 mg over six months.
Show in the study text Report a problemFND-4077771904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.